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Background: The objective of this study was to prepare, characterize, and evaluate a 
folate-modified self-microemulsifying drug delivery system (FSMEDDS) with the aim to 
improve the solubility of curcumin and its delivery to the colon, facilitating endocytosis of 
FSMEDDS mediated by folate receptors on colon cancer cells.
Methods: Ternary phase diagrams were constructed in order to obtain the most efficient 
self-emulsification region, and the formulation of curcumin-loaded SMEDDS was optimized 
by a simplex lattice experiment design. Then, three lipophilic folate derivatives (folate-
polyethylene glycol-distearoylphosphatidylethanolamine, folate-polyethylene glycol-cholesteryl 
hemisuccinate, and folate-polyethylene glycol-cholesterol) used as a surfactant were added to 
curcumin-loaded SMEDDS formulations. An in situ colon perfusion method in rats was used 
to optimize the formulation of FSMEDDS. Curcumin-loaded FSMEDDS was then filled into 
colon-targeted capsules and the in vitro release was investigated. Cytotoxicity studies and 
cellular uptake studies was used in this research.
Results: The optimal formulation of FSMEDDS obtained with the established in situ colon 
perfusion method in rats was comprised of 57.5% Cremophor® EL, 32.5% Transcutol® HP, 
10% Capryol™ 90, and a small amount of folate-polyethylene glycol-cholesteryl hemisuc-
cinate (the weight ratio of folate materials to Cremophor EL was 1:100). The in vitro release 
results indicated that the obtained formulation of curcumin could reach the colon efficiently and 
release the drug immediately. Cellular uptake studies analyzed with fluorescence microscopy 
and flow cytometry indicated that the FSMEDDS formulation could efficiently bind with the 
folate receptors on the surface of positive folate receptors cell lines. In addition, FSMEDDS 
showed greater cytotoxicity than SMEDDS in the above two cells.
Conclusion: FSMEDDS-filled colon-targeted capsules are a potential carrier for colon delivery 
of curcumin.
Keywords: curcumin, SMEDDS, folate receptor, colon targeting
Introduction
Curcumin, a polyphenol of turmeric, is derived from the rhizomes of Curcuma longa, 
which can suppress the tumorigenic activity of various cancers, such as the colon, 
duodenum, esophagus, forestomach, stomach, liver, breast, leukemia, oral cavity, and 
prostate.1,2 Five Phase I clinical trials have demonstrated the safety and tolerability of 
curcumin in colorectal cancer patients.3 In spite of this huge potential of curcumin as 
an effective chemotherapy agent against colon cancer, it has poor systemic   availability 
due to its low aqueous solubility, efficient first-pass effect, and some degree of intestinal 
metabolism when administered via the oral route. It has been demonstrated that a 
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large daily oral dose of 3.6 g of curcumin resulted in 
  pharmacologically efficacious levels in colorectal tissue.4
Current trends of curcumin in the treatment of colon 
cancer have concentrated on the development of potential 
delivery systems to increase its aqueous solubility and 
bioavailability as well as controlled delivery of curcumin 
at or around cancer tissues.5 Recently, much attention has 
been given to self-microemulsifying drug delivery systems 
(SMEDDS) to enhance the solubility, dissolution, and oral 
absorption for poorly water-soluble drugs, such as itracon-
azole, oridonin, coenzyme Q10, and zedoary essential oil.6–9 
SMEDDS is an isotropic and thermodynamically stable 
solution consisting of oil, surfactant, cosurfactant, and drug, 
which can spontaneously form oil-in-water microemulsion 
when mixed with water under gentle stirring. The microemul-
sion presents the drug in a dissolved form, and the small 
droplet size (less than 100 nm) provides a large interfacial 
surface area favoring drug absorption.
For efficient drug delivery, a carrier system should facili-
tate not only tumor localization but also intracellular access. 
Folate receptor is a glycosylphosphatidylinositol-linked 
membrane glycoprotein of 38 kDa, which is overexpressed 
on the surface of most solid tumors, including colorectal 
carcinoma.10 In recent years, it has been demonstrated that 
folate receptor-mediated uptake of the vitamin folic acid 
could be exploited to facilitate entry of an attached liposome 
or emulsion into cells.11,12
In the present study, an attempt was made to improve the 
solubility and targeted-delivery of curcumin to the colon by 
formulating it as folate-modified SMEDDS (FSMEDDS) and 
filling the formulation into colon-targeted capsules coated 
by Eudragit® S 100 (Evonik Industries AG, Essen Germany), 
a coating material for colonic delivery because of it will not 
dissolve under the condition of pH , 7.5 Under conditions 
of colon fluid, curcumin-loaded SMEDDS (CUR-SMEDDS) 
containing folate conjugated material can form a micro-
emulsion and then it can bind with folate receptors at the 
surface of colorectal tissues or colon cancer cells to increase 
the absorption in the colon or induce the endocytosis of 
CUR-FSMEDDS.10,13
The main objectives of this study were to develop and char-
acterize a CUR-SMEDDS formulation for colon targeting and 
to evaluate its anticancer effects. An efficient CUR-SMEDDS 
formulation was developed using solubility and phase dia-
grams. The formulation optimization of   CUR-FSMEDDS 
was conducted with the established in situ colon perfusion 
method in rats. The developed formulations were character-
ized by assessing morphology, particle size, and zeta potential. 
Cytotoxicity of SMEDDS and FSMEDDS was evaluated 
by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium 
bromide (MTT) assay (Sigma Chemical Co, St Louis, MO), 
and cellular uptake of the two formulations was investigated 
with fluorescence microscopy and flow cytometry.
Materials and methods
Materials
For preparation of the SMEDDS formulation, curcumin 
was purchased from Sigma-Aldrich Corporation (St Louis, 
MO). Capryol™ 90, Labrafil® M1944CS, Labrasol®, Plurol® 
Oleique CC 497, and Transcutol® HP were purchased from 
Gattefosse (Saint-Priest, France). Cremophor® EL was 
obtained from BASF (Ludwigshafen, Germany). Emulsifier 
OP, 1,2-propanediol, and Tween® 80 were purchased from 
Guangcheng Chemical Co, Ltd (Tianjin, China). Ethyl oleate 
and polyethylene glycol (PEG) 400 were purchased from 
Shanghai Chemical Co, Ltd (Shanghai, China). Ethanol was 
obtained from Fuyu Fine Chemical Co, Ltd (Tianjin, China). 
Castor oil and isopropyl myristate were purchased from 
Sinopharm Chemical Reagent Co, Ltd (Shanghai, China). 
Folate-PEG-cholesterol (F-PEG-Chol) was presented by 
Professor Guangya Xiang (School of Pharmacy, Huazhong 
University of Science and Technology, Wuhan, Hubei, 
China). For the cell culture experiment, folate-free Roswell 
Park Memorial Institute 1640 medium and Gibco® trypsin-
ethylenediaminetetraacetic acid were purchased from Life 
Technologies (Carlsbad, CA). Characterized fetal bovine 
serum was purchased from Hangzhou Sijiqing Biological 
Engineering Materials Co, Ltd (Hangzhou, China). Hela 
(human uterine cervix cancer cell line) and HT-29 (human 
colon carcinoma cell line) were purchased from the cell bank 
of the Chinese Academy of Science (Beijing, China). The 
MTT assay was purchased from Sigma-Aldrich.
SMEDDS formulation optimization
Solubility studies
Solubility studies were conducted by placing an excess 
amount of curcumin in a 2 mL tube containing 1 mL of oil, 
surfactant, and cosurfactant, as shown in Table 1. The mixture 
was then shaken in a water bath shaker at room temperature 
for 48 hours to get to equilibrium. The equilibrated sample 
was centrifuged at 12,000 rpm for 10 minutes, followed by 
filtration through a membrane filter (0.45 µm) to remove 
the undissolved curcumin. The supernatant was taken and 
diluted with methanol for quantification of curcumin by 
high-performance liquid chromatography system (Agilent 
1200 Infinity series; Agilent Technologies, Santa Clara, CA). 
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The high-performance liquid chromatography method used 
a phenomenex-C18 column (5 µm, 4.6 mm × 250 mm) at 
room temperature, and the mobile phase was a mixture of 
methanol:water (containing 3.6% glacial acetic acid) (73:27 
volume/volume). The flow rate was set at 1.0 mL/minute and 
the analysis wavelength was at 428 nm.
Construction of ternary phase diagrams
Ternary phase diagrams were constructed in order to obtain 
the concentration range of components for the existing region 
of microemulsions.14 The effect of various oils on the microe-
mulsion formation was studied by constructing ternary phase 
diagrams with Capryol 90 and Labrafil M1944CS at the oil 
phase, with Cremophor EL as the surfactant, and Transcutol 
HP as the cosurfactant. When Capryol 90 was fixed at the 
oil phase, the influence of various surfactants on the micro-
emulsion formation with Transcutol HP as cosurfactant and 
the influence of various cosurfactants on the microemulsion 
formation with Cremophor EL as surfactant were evaluated 
by constructing a ternary phase diagram.
Preparation and optimization of CUr-SMEDDS 
formulations
Blank SMEDDS formulations were obtained by   mixing the 
oil with surfactant and cosurfactant, which were selected 
by ternary phase diagrams under a magnetic   stirring 
at 400 rpm/minute for 3 minutes at room temperature. 
Curcumin was added to blank SMEDDS and mixed by gentle 
vortexing until a transparent preparation was obtained, then 
the CUR-SMEDDS was prepared. In this study, a simplex 
lattice experiment design was used to optimize the composi-
tions of SMEDDS formulation. The Simplex–Lattice experi-
ment design for a three-component system was represented 
by an equilateral triangle in a two-dimensional space.15,16 
Seven batches of CUR-SMEDDS were prepared as shown 
in Table 2.
Synthesis of lipophilic folate derivatives 
and optimization of CUr-FSMEDDS
Two lipophilic derivatives, folate-PEG-distearoylphosphati-
dylethanolamine (F-PEG-DSPE) and folate-PEG-cholesteryl 
hemisuccinate (F-PEG-CHEMS), were synthesized based on 
established methods.13,17,18 F-PEG-DSPE, F-PEG-CHEMS, or 
F-PEG-Chol was added to CUR-SMEDDS formulations as 
a surfactant. It has been previously reported that due to the 
existence of receptors such as lectin or transferrin receptors 
on the intestinal mucosa, relative ligands such as lectin and 
transferrin-modified nanoparticulate delivery systems could 
enhance the intestinal absorption of the drug through specific 
binding.19–21 Thus, it could be inferred that the folate-modified 
carriers would improve the absorption in the colon by the 
encapsulated drug binding with folate receptors on normal 
colorectal mucosa.10 The effect of different folate derivatives 
on the absorption in the colon of curcumin in FSMEDDS 
Table 1 Solubility of curcumin in various vehicles
Oils Solubility  
(mg/mL)a
Surfactants Solubility  
(mg/mL)a
Cosurfactants Solubility  
(mg/mL)a
Ethyl oleate 1.04 ± 0.02 Labrasol® 99.30 ± 1.73 1,2-propanediol   2.68 ± 0.25
Castor oil 1.56 ± 0.47 Cremophor® EL 65.83 ± 4.80 Ethanol   5.98 ± 0.63
Isopropyl myristate 0.51 ± 0.05 Emulsifier OP   5.16 ± 1.03 PEG 400 159.78 ± 0.48
Capryol™ 90 9.43 ± 0.80 Tween® 80   4.86 ± 1.15 Plurol® Oleique CC497   1.36 ± 0.13
Labrafil® M1944CS 3.17 ± 0.13 Transcutol® HP 140.56 ± 3.42
Note: aData presented as mean value ± standard error, n = 3. 
Abbreviation: PEG, polyethylene glycol.
Table 2 Actual and transformed values, mean particle size, and solubility of seven different formulations per Simplex–Lattice design
Formulation  
number
Formulation components/transformed fraction values Solubility  
(mg/g)a
Mean particle   
size (nm)a
Surfactant Cosurfactant Oil
1 60%/1 30%/0 10%/0 72.71 ± 1.41   29.13 ± 0.71
2 30%/0 60%/1 10%/0 73.18 ± 2.18 121.50 ± 12.02
3 30%/0 30%/0 40%/1 50.12 ± 0.83   36.37 ± 5.44
4 45%/0.5 45%/0.5 10%/0 63.76 ± 6.81   28.16 ± 0.07
5 45%/0.5 35%/0 25%/0.5 65.34 ± 7.48 216.35 ± 14.14
6 30%/0 45%/0.5 25%/0.5 62.60 ± 1.41 186.03 ± 3.39
7 40%/0.33 40%/0.33 20%/0.33 58.45 ± 3.78   232.3 ± 1.06
Note: aData presented as mean value ± standard error, n = 3.
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formulations was thus studied using the established in situ 
colon perfusion method in rats.22,23
Rats were fasted overnight with free access to water 
before the experiment. The rat was anesthetized by an intrap-
eritoneal injection of 1% sodium pentobarbital (0.4 mL/ 100 g 
body weight) and was placed under an infrared lamp to keep 
body temperature normal. Upon verification of the loss of 
pain reflexes, the abdomen was opened with a middle longi-
tudinal incision about 3 cm long. After the abdominal cavity 
was opened, the colon segment in perfusion was exposed 
and incisions were made on both sides of the segment. It 
was rinsed with physiological saline and then connected to a 
  constant-flow pump (BT00–100M; Baoding Longer   Precision 
Pump Co, Ltd, Baoding, China) with catheters to the perfu-
sion system. Curcumin-loaded microemulsion (25 mL) was 
prepared by dispersing CUR-SMEDDS or CUR-FSMEDDS 
containing different types and concentrations of lipophilic 
folate derivatives in a Krebs-Ringer buffer solution (Sigma-
Aldrich) at 37°C. Perfusion with the curcumin dose of 
50 mg/kg was introduced into colon segment loops with the 
pump at a flow rate of 2.5 mL/minute; both ends of the loop 
were ligated. The entire surgical area was covered with a piece 
of sterilized absorbent gauze wetted with normal saline. After 
6 hours, the effluent solution in the loop was collected and 
diluted by Krebs-Ringer buffer solution for determination.
Characterization of CUr-FSMEDDS
Morphology
The morphology of CUR-FSMEDDS was observed under 
transmission electron microscope (JEM-1200EX; JEOL 
Ltd, Tokyo, Japan). CUR-FSMEDDS was diluted with 
distilled water (1:100) and gently mixed, and then stained 
with a 2% aqueous solution of phosphotungstic acid and 
allowed to dry before observation under the transmission 
electron microscope.
Droplet size and zeta potential determination
CUR-FSMEDDS formulation (1 mL) was diluted with 
100 mL of deionized water under constant stirring. The 
droplet size distribution and zeta potential of the resultant 
microemulsion was determined by a particle size and zeta 
potential analyzer (Delsa™Nano; Beckman Coulter Inc, 
Brea, CA).
release of curcumin from  
FSMEDDS-filled colon-targeted capsules
CUR-FSMEDDS equivalent to 1 mg of curcumin were filled 
into colon-targeted capsules for rats (Qiangji Pharmaceutical 
Factory, Chaozhou, China) without shell damage. Release 
studies of CUR-FSMEDDS capsules in vitro were carried 
out in 150 mL of pH progression medium at 37°C ± 0.5°C, 
with the paddle operated at 50 rpm.24
The drug release from FSMEDDS was designed as fol-
lows: hour 0–2: drug release was carried out in the simulated 
gastric fluid (0.1 N hydrochloride) with pH 1.2 as dissolution 
medium; hour 2–5: drug release was performed in the simu-
lated intestinal fluid (6.8045 g monopotassium phosphate, 
118 mL of 0.2 N sodium hydroxide in 1000 mL of distilled 
water) with pH 6.8 as dissolution medium; hour 5–24: drug 
release was performed in the simulated colonic fluid (6.8 g 
monopotassium phosphate, 291 mL of 0.1 N sodium hydrox-
ide in 1000 mL of distilled water) with pH 7.4.
Samples (3 mL) were withdrawn and replaced with fresh 
media at 60, 120, 180, 240, 300, 305, 310, 320, 330, 345, 360, 
and 390 minutes. Samples were then filtered using a 0.45 µm fil-
ter and analyzed by an ultraviolet spectrophotometer (UV-2102; 
Shanghai Instrument Ltd, Shanghai,  China). Three separate 
replicate studies were conducted for each of the formulations 
and data presented as mean ± standard deviation (n = 3).
Cell culture
HT-29 and Hela cell lines were maintained in folate-free 
Roswell Park Memorial Institute 1640 media supplemented 
with 10% fetal bovine serum. The cells were incubated at 
37°C with 5% carbon dioxide. After reaching confluence, the 
cells were detached from the flask with trypsin-ethylenedi-
aminetetraacetic acid. The cell suspension was centrifuged 
at 800 rpm for 3 minutes and then resuspended in the growth 
medium for further experiments.
Cytotoxicity studies
Cytotoxicity of SMEDDS was determined by an MTT 
assay.11 Hela and HT-29 cells (5000/well) were seeded in 
a 96-well plate and allowed to attach for 24 hours. The 
medium was replaced with 100 µL of fresh folate-free 
medium and the cells were treated with 100 µL of differ-
ent concentrations of free curcumin (curcumin-dimethyl 
sulfoxide),   CUR-SMEDDS, and CUR-FSMEDDS with or 
without 1 mM of free folate (1, 5, 10, 20, 40 µM curcumin/
well). After being incubated for 24 hours at 37°C in a carbon 
dioxide incubator, the medium was removed and then fresh 
medium was added after cells were washed three times with 
phosphate buffered saline. Then, 20 µL of MTT (5 mg/mL in 
phosphate buffered saline) was added to the cells and incu-
bated for 4 hours at 37°C. The medium was then removed 
and replaced with 150 µL of dimethyl sulfoxide to dissolve 
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the blue formazan crystals converted from MTT by live 
cells. The optical density of each well was measured using 
a microplate reader (Model 680; Bio-Rad Laboratories, 
  Hercules, CA) equipped with a 570 nm filter. Triplicate 
samples were analyzed for each experiment.
Cellular uptake studies
Qualitative cellular uptake study
Coumarin 6 (Sigma-Aldrich) was used as a model hydrophobic 
fluorescent probe to be encapsulated in SMEDDS formulation. 
HT-29 and Hela cells were seeded in a 24-well plate at a 
density of 105 cells/well and allowed to attach for 24 hours. 
By replacing the contents with fresh medium, the cells were 
incubated with nontargeted Coumarin 6-loaded SMEDDS 
(Coumarin 6-SMEDDS) or Coumarin 6-FSMEDDS at 37°C 
for 0.5, 1, 2, 5, and 24 hours, respectively. To determine the 
role of folate receptor binding, 1 mM of free folate was added 
to the media in the folate receptor blocking group (Coumarin 
6-FSMEDDS) and incubated for 1 hour before adding drugs 
at different time intervals. All the wells were treated with 
15 µg/mL of Coumarin 6 for each formulation.25 At the end 
of incubation, the cells were washed three times with cold 
phosphate buffered saline to remove residual drugs, and the 
fluorescence images of Coumarin 6 in different cells were 
captured under a fluorescence microscope (BX 51; Olympus 
Corporation, Tokyo, Japan) using a blue filter.
Cellular uptake by flow cytometry
The cellular uptake of Coumarin 6 in SMEDDS and 
FSMEDDS formulations (with or without 1 mM folate) was 
formed by fluorescence-activated cell sorting analysis. Cells 
were seeded in a 6-well plate at a density of 106 cells/well. 
After reaching 90% confluence, 15 µg/mL of Coumarin 6 in 
different formulations was added and incubated at 37°C for 
2 hours. Intracellular Coumarin 6 fluorescence was analyzed 
with a flow cytometer (FACSCalibur™ system; Becton, 
Dickinson, and Company, Franklin Lakes, NJ).
Statistical analysis
Statistical data analyses were performed using Student’s t-test 
with the aid of IBM SPSS (v16.0; SPSS Inc, Chicago, IL). 
A value of P , 0.05 was considered statistically significant.
Results and discussion
Solubility studies
To develop a SMEDDS formulation for oral delivery of 
poorly water-soluble curcumin, a suitable oil, surfactant, and 
cosurfactant needed to be chosen. The solubility of curcumin 
in various vehicles are presented in Table 1. As shown 
in Table 1, curcumin showed good solubility in the oils 
Capryol 90 (9.43 ± 0.80 mg/mL) and Labrafil M1944CS 
(3.17 ± 0.13 mg/mL).
Surfactants Labrasol and Cremophor EL showed 
maximum drug solubilization (99.30 ± 1.73 mg/mL and 
65.83 ± 4.80 mg/mL, respectively). Cosurfactants Transcutol 
HP (140.56 ± 3.42 mg/mL) and PEG 400 (159.78 ± 0.48 mg/mL) 
exhibited higher solubility for curcumin. The high solubility 
in PEG 400, Cremophor EL, and Labrasol might be due to the 
ability of curcumin to form a hydrogen bond with the polyeth-
ylene oxide groups in above materials.26 The above excipients 
with high solubility for curcumin were used to construct the 
ternary phase diagrams.
Construction of ternary phase diagrams
Drug loading capability is the main factor when screening 
the oil phase. Curcumin showed higher solubility in 
Capryol 90 and Labrafil M1944CS. Their phase behaviors 
were compared by constructing ternary phase diagrams. 
The phase diagrams of the systems containing Cremophor 
EL as surfactant, Transcutol HP as cosurfactant, and 
different oils (Capryol 90 and Labrafil M1944CS) are 
shown in Figure 1A and B. A larger self-microemulsifying 
region was found, as shown in Figure 1A. Hence, Capryol 
90 was selected at oil phase. Two phase diagrams were 
constructed with Capryol 90 as the oil, Transcutol HP as 
cosurfactant, and different surfactants (Cremophor EL or 
Cremophor EL:Labrasol [1:1]). As shown in Figure 1C, the 
self-microemulsion region of the formulation containing 
Cremophor EL was larger than that containing Cremophor 
EL:Labrasol (1:1). Therefore, the desirable surfactant 
should be Cremophor EL.
As to the selection of a cosurfactant, Capryol 90 and 
Cremophor EL were used as oil phase and surfactant, 
respectively. As shown in Figure 1D and E, the solubility 
of curcumin in PEG 400 was higher than that in Transcutol 
HP or in ethanol. However, compared with Transcutol HP, 
PEG 400 had relatively higher hydrophilic properties, which 
could increase the risk of destroying the microemulsion.26 In 
addition, the self-microemulsion region of Transcutol HP was 
larger compared with that of PEG 400 or ethanol. Therefore, 
Transcutol HP was selected as the cosurfactant.
Preparation and optimization  
of CUr-SMEDDS formulations
A Simplex–Lattice design was used to optimize the 
  composition of CUR-SMEDDS. In view of the feasibility of 
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SMEDDS formation, according to the ternary phase   diagrams 
shown in Figure 1, the ranges of the three factors were 
selected as follows: surfactant percentage (X1), 30%–60%; 
cosurfactant percentage (X2), 30%–60%; oil percentage 
(X3), 10%–40%. Seven formulations containing curcumin 
were conducted (Table 2). In order to achieve a high drug 
loading and a uniform droplet size (,100 nm), solubility and 
mean particle size of the seven formulations were selected 
as evaluation indexes.
The results were processed with a MATLAB® 7.0 data-
processing system (MathWorks, Natick, MA) and the equations 
for solubility and mean particle size were as follows:
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Figure 1 Ternary phase diagrams studies for selecting of oil, surfactant, and cosurfactant. 
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•	 Ysolubility = 50.16 + 14.79[CoS] – 543.59[O] – 88.89[S]
[CoS] + 1665.8[S][O] + 1533.6[CoS][O] – 4971.1[S]
[CoS][O], (R2 = 0.9999)
•	 Yparticle size = 242.3 + 647.9222[CoS] + 39.0667[O] 
– 8268.4[S][CoS] – 10358[S][O] – 13758 [CoS]
[O] + 61727[S][CoS][O], (R2 = 0.9999).
In the two equations, CoS represents the cosurfactant,   
S the surfactant, and O the oil. All the obtained coefficients 
R2 are larger than 0.95, indicating that over 95% of the 
variation in response could be explained with this model, 
and the agreement of fit to the model was confirmed. As 
shown in Table 2, particle size increased and the solubility 
of curcumin decreased with the increase of the ratio of oil 
in the formulation. In order to obtain suitable particle size 
and high solubility of curcumin, the percentage of oil was 
set at 10%.27 Based on the two equations, contour plots of 
solubility and mean particle size were constructed (Figure 2). 
Trace contours were constructed when Ysolubility was equal to 
60, 65, and 70 mg/g as shown in Figure 2A. In Figure 2B, 
three mean particle size curves stood for 10 nm, 50 nm, and 
100 nm. The optimized formulation was chosen by superim-
posing the contour plots of the two responses (Figure 2C). 
The common section between Yparticle size (located at the field of 
10–50 nm) and Ysolubility (located at the scope of 65–70 mg/g) 
was the best area for the concentrations of surfactant 
and cosurfactant.
Based on solubility for curcumin and the mean particle 
size of the formed microemulsion, the composition of opti-
mized formulation was chosen as follows: 57.5% surfactant 
(Cremophor EL), 32.5% cosurfactant (Transcutol HP), and 
10% oil (Capryol 90). To confirm the model’s adequacy 
for prediction, three batches of CUR-SMEDDS under the 
optimum composition were prepared, and the two responses 
(Ysolubility and Yparticle size) were evaluated. The results presented 
in Table 3 show the predicted values of mean particle size 
and solubility of SMEDDS calculated by equations were 
close to those obtained from the experiment.
Synthesis of lipophilic folate derivatives
The structures of the synthesized F-PEG-DSPE and F-PEG-
CHEMS were confirmed by hydrogen-1 nuclear magnetic 
resonance, and the spectrograms for the two materials are 
shown in Figure 3. For F-PEG-CHEMS, hydrogen-1 nuclear 
magnetic resonance analysis showed principal peaks (in ppm) 
related to the folate moiety (8.11 [double peaks; d], 7.63 [d], 
6.93 [three peaks; t], 6.63 [d], 4.48 [d], 4.30 [mixed peaks; m]), 
the PEG moiety (3.65 [m]) and the CHEMS moiety (5.34 [d], 
4.5 [m], 0.65–2.30 [m]), which was similar to a previous report.18 
0.3
0.3
0.35
0.4
0.45
0.5
0.55
70
65
65
60
70
60
0.35 0.4 0.45 0.5 0.55 0.6
0.3
0.3
0.35
0.4
0.45
C
o
S
C
o
S
S
S
0.55
100
10
50
0.5
0.35 0.4 0.45 0.5 0.55 0.6
0.3
0.3
0.35
0.4
0.45
0.5
0.55
70
65
100
10
60
50
60
S
C
o
S
65
70
0.35 0.40 .450 .5 0.55 0.6
C
B
A
Figure 2 The contour plots of response for the contour plot of mean particle size 
(A), the contour plot of solubility (B), and the mixed contour plot of mean particle 
size and solubility (C). 
Abbreviations: S, surfactant; CoS, cosurfactant.
Moreover, the structure of F-PEG-DSPE was corroborated by 
hydrogen-1 nuclear magnetic resonance, and the main peaks (in 
ppm) for the folate moiety (8.63 [small peaks; s], 7.68 [d], 6.62 [d], 
4.47 [d]), the PEG moiety (3.65 [m]) and the DSPE moiety (0.85 
[t], 1.23 [s], 1.49 [d], 2.24 [d]) confirmed the structure of F-PEG-
DSPE, which was in accordance with a previous study.28
Table 3 The predicted values and the experimental results of 
the curcumin-loaded self-microemulsifying drug delivery system 
prepared under the optimum conditions
Response Predicted  
value
Experimental  
valuea
Bias (%)
Solubility (mg/g) 69.95 67.32 ± 0.92 3.91
Particle size (nm) 22.43   24.6 ± 0.42 8.82
Notes: Bias (%) = ([predicted value – experimental value]/experimental value) × 100; 
adata presented as mean value ± standard error, n = 3.
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Optimization of CUr-FSMEDDS
Folate receptor is overexpressed in many tumors and enables 
the endocytosis of folate-conjugated carriers. Thus, folate 
is an attractive tumor-targeting ligand in the cell-specific 
delivery systems.29 Currently, lipophilic folate derivatives, 
such as F-PEG- DSPE, F-PEG-CHEMS, and F-PEG-Chol 
were used to enhance the accumulation of formulations in 
the tumor.12,17,30 Except for these, folate receptor was proven 
to exist in normal colorectal mucosa, which could lead to the 
endocytosis of folate material and an increase in the absorption 
of drug in the colon.10 In order to evaluate the effect of differ-
ent types and concentrations of lipophilic folate derivatives in 
SMEDDS on the absorption of curcumin in colon mucosa, a 
colon perfusing experiment in rats was performed.27
CUR-FSMEDDS was prepared by adding lipophilic 
folate derivatives into the mixture of surfactant, cosurfactant, 
and oil. The absorption percentage of curcumin in the colon 
for 6 hours was calculated using the formula: P = (C0V0/
C1V1) × 100%, where C0V0 is the original concentration and 
volume and C1V1 is the resulting concentration and volume. 
When the weight ratio of folate conjugated materials to 
Cremophor EL was at 3:100, the absorption percentage 
of the formulation containing F-PEG-CHEMS showed 
no significant difference compared with that containing 
F-PEG-DSPE or F-PEG-Chol (P . 0.05), but showed 
a significant difference compared with CUR-SMEDDS 
(P , 0.05) (Table 4). Moreover, the two negative charges in 
F-PEG-DSPE and a carbamate linker in F-PEG-Chol could 
limit their hydrolytic stability.18 Thus, F-PEG-CHEMS was 
chosen for concentration screening. Three weight ratios of 
F-PEG-CHEMS to Cremophor EL (0.5:100, 1:100, and 
3:100) were evaluated, and the formulation in which the 
weight ratio of F-PEG-CHEMS to Cremophor EL was 1:100 
had the maximum absorption percentage among the studied 
preparations (P , 0.05). Therefore, the final formulation 
of FSMEDDS was comprised of 57.5% Cremophor EL, 
32.5% Transcutol HP, 10% Capryol 90 with a small amount 
of F-PEG-CHEMS (the weight ratio of folate materials 
to Cremophor EL was 1:100). After the incorporation of 
F-PEG-CHEMS, the solubility of curcumin in FSMEDDS 
was 66.59 ± 1.21 mg/g, which was not significantly different 
compared with that in SMEDDS (67.32 ± 0.92 mg/g) 
(P . 0.05). However, the solubility of curcumin in the 
aqueous medium was about 11 ng/g.31,32 Therefore, it could 
be concluded that FSMEDDS increased the solubility of 
curcumin in water more than 6 × 106-fold.
Characterization of CUr-FSMEDDS
CUR-FSMEDDS can form into microemulsion when diluted 
with distilled water. As shown in the transmission electron 
microscope picture (Figure 3), the microemulsion droplets 
appeared spherical without aggregation. The parameters for 
physicochemical characters of the optimized formulation are 
shown in Table 5. For blank FSMEDDS, droplet size was sig-
nificantly increased with the incorporation of F-PEG-CHEMS 
(P , 0.05). The long PEG-spacer in F-PEG-CHEMS dispersing 
into the emulsifying membrane layer (composed of surfactant 
and cosurfactant) might lead to increased droplet size. As 
seen in Table 5, the addition of   curcumin in SMEDDS and 
50 nm
Figure 3 Transmission electron microscope micrographs of curcumin-loaded self-
microemulsifying drug delivery system with the scale bar for the image representing 
50 nm. 
Table 4 The absorption percentage of curcumin in different formulations with the established in situ colon perfusion method in rats 
for 6 hours
Formulations Absorption percentage (%)a
CUr-SMEDDS without folate material 58.41 ± 7.26
CUr-FSMEDDS with weight ratio of F-PEG-CHEMS to Cremophor® EL at 3:100 67.14 ± 3.72
CUr-FSMEDDS with weight ratio of F-PEG-DSPE to Cremophor® EL at 3:100 62.66 ± 4.33
CUr-FSMEDDS with weight ratio of F-PEG-Chol to Cremophor® EL at 3:100 64.96 ± 3.13
CUr-FSMEDDS with weight ratio of F-PEG-CHEMS to Cremophor® EL at 0.5:100 62.11 ± 2.16
CUr-FSMEDDS with weight ratio of F-PEG-CHEMS to Cremophor® EL at 1:100 73.38 ± 3.12
Note: aData presented as mean value ± standard error, n = 3.
Abbreviations: CUR-FSMEDDS, curcumin-loaded folate-modified self-microemulsifying drug delivery system; CUR-SMEDDS, curcumin-loaded self-microemulsifying drug 
delivery  system;  F-PEG-CHEMS,  folate-polyethylene  glycol-cholesteryl  hemisuccinate;  F-PEG-Chol,  folate-polyethylene  glycol-cholesterol;  F-PEG-DSPE,  folate-polyethylene 
glycol- distearoyl-phosphatidylethanolamine.
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FSMEDDS significantly increased droplet size after diluting 
with distilled water (P , 0.05), which was in accordance with 
another study.27 The zeta potential is an electrostatic value 
measured by surface electrostatic double layer of droplets. As 
shown in Table 5, the absolute zeta potential value of CUR-
SMEDDS was significantly higher than that of blank SMEDDS 
(P , 0.05). The possible reason being that the formation of 
intermolecular hydrogen bonds among the hydroxyl groups 
in curcumin and some relative groups containing oxygen or 
nitrogen atoms in surfactant, cosurfactant, and oil produced the 
change in the surface electrostatic double layer of droplets.33
release of curcumin from FSMEDDS-
filled capsules for colon targeting
The optimized SMEDDS formulations were filled volumetri-
cally in colon-targeted gelatin capsules coated with Eudragit® 
S 100 (Evonik Industries, Essen, Germany).
In vitro release studies were carried out in order to evalu-
ate the effect of colon-targeted capsules with the objective 
of releasing most of the drug in the colon. An ideal formula-
tion for site-specific delivery of the drug to the colon should 
suppress the drug’s release in the upper gastrointestinal tract 
and once transported to the colon, the drug should release 
rapidly. Figure 4 shows the drug release from the colon-
targeted capsules filled with CUR-FSMEDDS in simulated 
  gastrointestinal tract fluids. At pH 1.2 about 5% of the drug 
amount was released from the capsule in the following 3 hours 
and (in simulated intestinal fluid with pH 6.8), about 13% of 
curcumin was released from the capsule. In conclusion, in 
the first 5 hours, less drug was released from the capsules, 
which was attributed to the insolubility of Eudragit S 100 in 
low pH. However, after the capsules were transferred into 
simulated colonic fluid (pH 7.4) for 150 minutes, about 77% 
of the drug was released from the capsules, which was due 
to the dissolution of capsules and the formation of curcumin 
microemulsion. The results indicated that drug was protected 
from the upper gastrointestinal tract by the colon-targeted 
capsules, and this formulation of curcumin could reach the 
colon efficiently and release the drug immediately.
Cytotoxicity studies
Cytotoxicity of blank SMEDDS, blank FSMEDDS, CUR-
SMEDDS, CUR- FSMEDDS, free folate + CUR-SMEDDS, 
and free curcumin were studied using MTT assay, and their 
concentrations leading to 50% cell death were determined 
from concentration-dependent cell viability curves. As shown 
in Table 6, the 50% cell death value for CUR-FSMEDDS 
was lower than that for CUR-SMEDDS and free curcumin 
(P , 0.05), which may be because the receptor-mediated 
endocytosis increased the accumulation in the cell of cur-
cumin from FSMEDDS.13 The 50% cell death value for CUR-
FSMEDDS increased when 1 mM folate was first added in 
both Hela and HT-29 cells (P , 0.05). The results suggested 
that free folate in the medium could prevent CUR-FSMEDDS 
transport into cells by competitively binding to folate recep-
tors on the cell surface. The much higher cytotoxicity of free 
curcumin compared with CUR-SMEDDS may be a result 
of when cells were exposed to free curcumin in dimethyl 
sulfoxide or CUR-SMEDDS for the same amount of time, 
leading to more rapid free curcumin uptake.13
Cellular uptake studies
Although curcumin demonstrates autofluorescence, its fluo-
rescence intensity was weak in the preliminary experiment. 
  Therefore, Coumarin 6 was used as a model hydrophobic 
Table 5 Mean particle size and zeta potential of different self-microemulsifying drug delivery system formulations
Samples Mean particle size (nm)a Polydispersity indexa Zeta potential (mV)a
Blank SMEDDS 23.7 ± 0.78 0.273 ± 0.008 -1.65 ± 0.68
Blank FSMEDDS 27.3 ± 0.64 0.046 ± 0.004 -1.93 ± 0.39
Curcumin-loaded SMEDDS 27.6 ± 0.42   0.32 ± 0.005 -5.56 ± 0.97
Curcumin-loaded FSMEDDS 31.1 ± 0.99   0.30 ± 0.06 -6.56 ± 0.49
Note: aData presented as mean value ± standard error, n = 3. 
Abbreviations: FSMEDDS, folate-modified self-microemulsifying drug delivery system; SMEDDS, self-microemulsifying drug delivery system.
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Figure 4 Dissolution profiles of curcumin from curcumin-loaded folate-modified 
self-microemulsifying  drug  delivery  system  colon-targeted  capsules  in  stimulated 
gastrointestinal fluids of different pH at a speed of 50 rpm. 
Note: results are represented by mean ± standard deviation (n = 3).
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  fluorescent probe in this study.34 Uptake by HT-29 and Hela 
cells of microemulsions formed from SMEDDS in culture 
media was analyzed with fluorescence   microscopy and 
flow cytometry. As shown in Figure 5, more FSMEDDS 
fluorescently-labeled cells could be clearly visualized 
compared with SMEDDS and the intensity of fluorescence 
decreased when 1 mM folate was added to the medium, 
  indicating folate-mediated endocytosis of FSMEDDS could be 
blocked by competitively binding to folate receptors on the cell 
surface. These microemulsions formed from SMEDDS were 
found to rapidly associate with folate receptor-positive HT-29 
and Hela cells in the initial 30   minutes. The fluorescence inten-
sity increased along with the extension of incubation time, and 
remained almost steady even after 48 hours, suggesting the 
Table 6 Cytotoxicities of various curcumin to Hela and HT-29 cells
Treatment group (Hela) IC50 (μM)a Treatment group (HT-29) IC50 (μM)a
CUr-FSMEDDS 18.27 ± 1.13 CUr-FSMEDDS 20.57 ± 0.78
CUr-FSMEDDS + 1 mM folate 27.27 ± 1.56 CUr-FSMEDDS + 1 mM folate 30.31 ± 2.71
CUr-SMEDDS 36.69 ± 1.04 CUr-SMEDDS 38.59 ± 0.17
Free curcumin   30.4 ± 1.71 Free CUr 25.62 ± 2.23
Note: aData presented as mean value ± standard error, n = 3. 
Abbreviations: CUR-FSMEDDS, curcumin-loaded folate-modified self-microemulsifying drug delivery system; CUR-SMEDDS, curcumin-loaded self-microemulsifying drug 
delivery system; IC50, 50% cell killing; Hela cells, human uterine cervix cancer cell line; HT-29 cells, human colon carcinoma cell line.
FSMEDDS SMEDDS
0.5 h
2 h
5 h
24 h
1 h
0.5 h
2 h
5 h
24 h
1 h
FSMEDDS + FA Control FSMEDDS SMEDDS FSMEDDS+FA Control AB
Figure 5 Fluorescence microscopy images showcasing the time dependent (0.5, 1, 2, 5, and 24 hours) intracellular uptake of Coumarin 6 from Coumarin 6-loaded self-microemulsifying 
drug delivery system, Coumarin 6-loaded folate-modified self-microemulsifying drug delivery system, and Coumarin 6-loaded folate-modified self-microemulsifying drug delivery 
system+1mM folic acid  by HT-29 (human colon carcinoma cell line) (A) and Hela (human uterine cervix cancer line) cells (B), the concentration of Coumarin 6 is 15 μg/mL.
Abbreviations: FA, folic acid; FSMEDDS, folate-modified self-microemulsifying drug delivery system; h, hours; SMEDDS, self-microemulsifying drug delivery system.
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retention of Coumarin 6 from SMEDDS localized inside the 
cells.35 Flow cytometric analysis was performed after incuba-
tion at 37°C for 2 hours. Similarly, the flow cytometry results 
in Figure 6 show that the cellular uptake of folate receptor-
targeted SMEDDS was much greater than that of nontargeted 
SMEDDS and the uptake was partly blocked by 1 mM free 
folate. All of these results indicated that the CUR-FSMEDDS 
formulation was transported into Hela and HT-29 cells via 
a folate receptor-mediated endocytosis process.
Conclusion
In this study, an FSMEDDS formulation was developed 
which could improve the solubility of curcumin and target 
the folate receptor in colon cancer cells. Compositions of 
SMEDDS were selected with ternary phase diagrams, and 
the formulation of CUR-SMEDDS was optimized by a 
Simplex–Lattice experiment design. The effect of different 
folate derivatives such as F-PEG-CHEMS, F-PEG-DSPE, 
and F-PEG-Chol in SMEDDS on the absorption of curcumin 
in colon mucosa was studied with a colon perfusing experi-
ment in rats. The results showed the absorption percentage 
of SMEDDS containing F-PEG-CHEMS in rat colons was 
better than that containing F-PEG-DSPE or F-PEG-Chol 
at the same concentration, and CUR-FSMEDDS with the 
weight ratio of F-PEG-CHEMS to Cremophor EL at 1:100 
was higher compared with when the ratio was at 0.5:100 
or 3:100. In addition, cytotoxicity and cellular uptake 
studies indicated that due to folate-mediated endocytosis, 
FSMEDDS showed a higher ability to actively target tumor 
cells with overexpressed folate receptors on the cell surface 
in   comparison with SMEDDS. In addition, the in vitro release 
of CUR-FSMEDDS in colon-targeted capsules showed this 
formulation of curcumin can reach the colon efficiently and 
release the drug immediately. It could be concluded that 
FSMEDDS-filled colon-targeted capsules are a potential 
carrier for colon delivery of curcumin.
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